Mechanisms of cellular anthracycline resistance in childhood acute leukemia

Leukemia

Volumn 12, Issue 11, 1998, Pages 1657-1670

  Den Boer, M L ^a   Pieters, R ^a   Veerman, A J P ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Daunorubicin; Doxorubicin; Idarubicin; Leukemia; Multidrug resistance

Indexed keywords

ANTHRACYCLINE; DAUNORUBICIN; DNA TOPOISOMERASE; DOXORUBICIN; EPIRUBICIN; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; IDARUBICIN; MULTIDRUG RESISTANCE PROTEIN; REGULATOR PROTEIN; TELOMERASE;

CELL DEATH; CELL MEMBRANE TRANSPORT; CHILDHOOD LEUKEMIA; DNA REPLICATION; DRUG BIOAVAILABILITY; DRUG DETOXIFICATION; DRUG MECHANISM; DRUG TARGETING; DRUG TRANSPORT; GENE EXPRESSION; HUMAN; LUNG RESISTANCE; MOLECULAR CLONING; PEDIATRICS; PRIORITY JOURNAL; REVIEW;

EID: 0031754926     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401175     Document Type: Review

References (28)

1. Jacquillat C, Boiron M, Weil M, Tanzer J, Najean Y, Bernard J. Rubidomycin - a new agent active in the treatment of acute lymphoblastic leukaemia. Lancet 1966; 2: 27-28.
2. Henze C, Fengler R, Hartmann R, Kornhuber B, Janka-Schaub G, Niethammer D, Riehm H. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group, Blood 1991; 78: 1166-1172.
3. Sadowitz PD, Smith SD, Shuster J, Wharam MD, Buchanan GR, Rivera GK. Treatment of late bone marrow relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1993; 81: 602-609.
4. Steuber CP, Krischer J, Holbrook T, Camitta B, Land V, Sexauer C, Mahoney D, Weinstein H. Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: a Pediatric Oncology Group randomized phase II study. J Clin Oncol 1996; 14: 1521-1525.
5. Den Boer ML, Pieters R, Kazemier KM, Rottier MMA, Zwaan CM, Kaspers GJL, Janka-Schaub G, Henze G, Creutzig U, Scheper RJ, Veerman AJP. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood 1998; 91: 2092-2098.
6. Klumper E, Pieters R, Veerman AJP, Huismans DR, Loonen AH, Hählen K, Kaspers GJL, Van Wering ER, Hartmann R, Henze G. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood 1995; 86: 3861-3868.
7. Pieters R, Den Boer ML, Durian M, Janka-Schaub GE, Schmiege-low K, Kaspers GJL, Van Wering ER, Veerman AJP. In vitro drug resistance testing in infant acute lymphoblastic leukemia cells - implications for treatment. Leukemia 1998 (in press).
8. Chaires JB, Dattagupta N, Crothers DM. Studies on interaction of anthracycline antibiotics and deoxyribonucleic acid: equilibrium binding studies on interaction of daunomycin with deoxyribonucleic acid. Biochemistry 1982; 21: 3933-3940.
9. Bachur NR, Yu F, Johnson R, Hickey R, Wu Y, Malkas L. Helicase inhibition by anthracycline anticancer agents. Mol Pharmacol 1992; 41: 993-998.
10. Nitiss JL, Beck WT. Antitopoisomerase drug action and resistance. Eur J Cancer 1996; 32A: 958-966.
11. Mizuno NS, Zakis B, Decker RW. Binding of daunomycin to DNA and the inhibition of RNA and DNA synthesis. Cancer Res 1975; 35: 1542-1546.
12. Sinha BK, Politi PM. Anthracyclines. In: Pinedo HM, Chabner BA, Longo DL (eds). Cancer Chemotherapy and Biological Response Modifiers Annual 11. Elsevier Science: Amsterdam, 1990, pp 45-57.
13. Burke TG, Sartorelli AC, Tritton TR. Selectively of the anthracyclines for negatively charged model membranes: role of the amino group. Cancer Chemother Pharmacol 1988; 21: 274-280.
14. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. New Engl J Med 1991; 324: 808-815.
15. Tritton TR. Cell surface actions of adriamycin. Pharmacol Ther 1991; 49: 293-309.
16. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med 1996; 2: 574-577.
17. Tritton TR, Yee G. The anticancer agent adriamycin can be actively cytotoxic without entering cells. Science 1982; 217: 248-250.
18. Tokes ZA, Rogers KE, Rembaum A. Synthesis of adriamycin-coupled polyglutaraldehyde microspheres and evaluation of their cytostatic activity. Proc Natl Acad Sci USA 1982; 79: 2026-2030.
19. Barabas K, Sizensky JA, Faulk WP. Transferrin conjugates of adriamycin are cytotoxic without intercalating nuclear DNA. J Biol Chem 1992; 267: 9437-9442.
20. Escriba PV, Ferrer-Montiel AV, Ferragut JA, Gonzalez-Ros JM. Role of membrane lipids in the interaction of daunomycin with plasma membranes from tumor cells: implications in drug-resistance phenomena. Biochemistry 1990; 29: 7275-7282.
21. Le Moyec L, Tatoud R, Degeorges A, Calabresse C, Bauza G, Eugène M, Calvo F. Proton nuclear magnetic resonance spectroscopy reveals cellular lipids involved in resistance to adriamycin and taxol by the K562 leukemia cell line. Cancer Res 1996; 56: 3461-3467.
22. Guffy MM, North JA, Burns CP. Effect of cellular fatty acid alteration on adriamycin sensitivity in cultured L1210 murine leukemia cells. Cancer Res 1984; 44: 1863-1866.
23. Zijlstra JG, De Vries EGE, Muskiet FAJ, Martini IA, Timmer-Bosscha H, Mulder NH. Influence of docosahexaenoic acid in vitro on intracellular adriamycin concentration in lymphocytes and human adriamycin-sensitive and -resistant small-cell lung cancer cell lines, and on cytotoxicity in the tumor cell lines. Int J Cancer 1987; 40: 850-856.
24. Holleran WM, DeGregorio MW, Ganapathi R, Wilbur JR, Macher BA. Characterization of cellular lipids in doxorubicin-sensitive and -resistant P388 mouse leukemia cells. Cancer Chemother Pharmacol 1986; 17: 11-15.
25. Callaghan R, Van Gorkom LCM, Epand RM. A comparison of membrane properties and composition between cell lines selected and transfected for multi-drug resistance. Br J Cancer 1992; 66: 781-786.
26. Berman E, McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 1992; 79: 3267-3273.
27. Speth PAJ, Minderman H, Haanen C. Idarubicin vs daunorubicin; preclinical and clinical pharmacokinetic studies. Semin Oncol 1989; 16: 2-9.
28. Siegfried JM, Burke TG, Tritton TR. Cellular transport of anthracyclines by passive diffusion. Biochem Pharmacol 1985; 34: 593-598.